Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jun 27;19(6):e0304077.
doi: 10.1371/journal.pone.0304077. eCollection 2024.

Demonstrating service delivery models for effective initiation and retention on pre-exposure prophylaxis (PrEP) among female bar workers in Dar es Salaam, Tanzania: A double randomized intervention study protocol

Joy J Chebet  1 , Winfrida Onesmo Akyoo  2 , Hannah Goymann  3 , Guy Harling  4   5   6   7   8 , Dale A Barnhart  5 , Idda H Mosha  2 , Doreen Donald Kamori  9 , Monica Gandhi  10 , Theodora Mbunda  11 , Judith Kipeleka  11 , David Sando  11 , Donna Spiegelman  12   13   14   15 , Rose Mpembeni  16 , Till Bärnighausen  3   6   11
Affiliations
Randomized Controlled Trial

Demonstrating service delivery models for effective initiation and retention on pre-exposure prophylaxis (PrEP) among female bar workers in Dar es Salaam, Tanzania: A double randomized intervention study protocol

Joy J Chebet et al. PLoS One. .

Abstract

Background: Pre-Exposure Prophylaxis (PrEP) has demonstrated efficacy in preventing HIV infection. Female Bar Workers (FBWs) often act as informal sex workers, placing them at risk of HIV infection. Despite expressing interest in PrEP, FBWs face barriers to accessing public-sector clinics where PrEP is delivered. We developed a study to compare the effectiveness of workplace-based PrEP provision to standard-of-care facility-based provision for PrEP initiation, retention and adherence among FBWs.

Methods: In this double-randomized intervention study, FBWs aged 15 years and above will be screened, consented and initiated on PrEP (emtricitabine/tenofovir disoproxil), and followed for six months. Participants will be randomized at the bar level and offered PrEP at their workplace or at a health facility. Those who are initiated will be independently individually randomized to either receive or not receive an omni-channel PrEP champion intervention (support from an experienced PrEP user) to improve PrEP adherence. We expect to screen 1,205 FBWs to enroll at least 160 HIV negative women in the study. Follow-up visits will be scheduled monthly. HIV testing will be performed at baseline, month 1, 4 and 6; and TDF testing at months 2 and 6. Primary outcomes for this trial are: (1) initiation on PrEP (proportion of those offered PrEP directly observed to initiate PrEP); and (2) adherence to PrEP (detectable urine TDF drug level at 6-months post-enrollment). The primary outcomes will be analyzed using Intention-to-Treat (ITT) analyses.

Discussion: Using a randomized trial design, we will evaluate two interventions aiming to reduce barriers to uptake and retention on PrEP among FBWs, a vulnerable population at risk of HIV acquisition and onward transmission. If these interventions prove effective in promoting PrEP among FBWs, they could assist in abating the HIV epidemic in Africa.

Trial registration: Registered with German Clinical Trials Register (www.drks.de) on 29 April 2020; Registration number DRKS00018101.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests exist.

Figures

Fig 1
Fig 1. Study schedule of enrollment, interventions and assessments.
Fig 2
Fig 2. Randomization and group assignments.
Fig 3
Fig 3. Minimum detectable effect size for PrEP initiation and adherence among Female Bar Workers, comparing workplace-based initiation to facility-based initiation.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization. Guideline on When To Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV [Internet]. World Heal. Organ. 2015. Available from: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/ - PubMed
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al.. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med [Internet]. 2012;367:399–410. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1108524 - DOI - PMC - PubMed
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al.. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med [Internet]. 2012;367:423–34. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1110711 - DOI - PubMed
    1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al.. Articles Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90. - PubMed
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al.. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med [Internet]. Massachusetts Medical Society; 2010;363:2587–99. Available from: 10.1056/NEJMoa1011205 - DOI - PMC - PubMed

Publication types

Grants and funding

This study is funded by the Heidelberg Institute of Global Health at Heidelberg University Hospital. GH is supported by a fellowship from the Wellcome Trust and Royal Society (210479/Z/18/Z). DS is supported by the following grants: NIH DP1ES025459, and R01AI112339. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.